These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 29067992)
1. Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts. Hill KP; Palastro MD Pol Arch Intern Med; 2017 Nov; 127(11):785-789. PubMed ID: 29067992 [TBL] [Abstract][Full Text] [Related]
2. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation. Krcevski-Skvarc N; Wells C; Häuser W Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767 [TBL] [Abstract][Full Text] [Related]
3. [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy]. Amato L; Minozzi S; Mitrova Z; Parmelli E; Saulle R; Cruciani F; Vecchi S; Davoli M Epidemiol Prev; 2017; 41(5-6):279-293. PubMed ID: 29119763 [TBL] [Abstract][Full Text] [Related]
4. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. Hill KP JAMA; 2015 Jun 23-30; 313(24):2474-83. PubMed ID: 26103031 [TBL] [Abstract][Full Text] [Related]
12. Medical use of cannabis in Switzerland: analysis of approved exceptional licences. Kilcher G; Zwahlen M; Ritter C; Fenner L; Egger M Swiss Med Wkly; 2017; 147():w14463. PubMed ID: 28695562 [TBL] [Abstract][Full Text] [Related]
13. The cannabis paradox. Ladouceur R Can Fam Physician; 2018 Feb; 64(2):86. PubMed ID: 29449225 [No Abstract] [Full Text] [Related]
14. The use of medical-grade cannabis in patients non-responders to Nabiximols. Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663 [No Abstract] [Full Text] [Related]
15. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis]. Basinski H; Jensen HB; Stenager E Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886 [TBL] [Abstract][Full Text] [Related]
16. Medical use of cannabis products: Lessons to be learned from Israel and Canada. Ablin J; Ste-Marie PA; Schäfer M; Häuser W; Fitzcharles MA Schmerz; 2016 Feb; 30(1):3-13. PubMed ID: 26767992 [TBL] [Abstract][Full Text] [Related]
17. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. Busse JW; Vankrunkelsven P; Zeng L; Heen AF; Merglen A; Campbell F; Granan LP; Aertgeerts B; Buchbinder R; Coen M; Juurlink D; Samer C; Siemieniuk RAC; Kumar N; Cooper L; Brown J; Lytvyn L; Zeraatkar D; Wang L; Guyatt GH; Vandvik PO; Agoritsas T BMJ; 2021 Sep; 374():n2040. PubMed ID: 34497062 [TBL] [Abstract][Full Text] [Related]
18. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Weinkle L; Domen CH; Shelton I; Sillau S; Nair K; Alvarez E Mult Scler Relat Disord; 2019 Jan; 27():383-390. PubMed ID: 30502644 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Whiting PF; Wolff RF; Deshpande S; Di Nisio M; Duffy S; Hernandez AV; Keurentjes JC; Lang S; Misso K; Ryder S; Schmidlkofer S; Westwood M; Kleijnen J JAMA; 2015 Jun 23-30; 313(24):2456-73. PubMed ID: 26103030 [TBL] [Abstract][Full Text] [Related]